0000000000876587
AUTHOR
Marie Chupin
showing 4 related works from this author
MOESM2 of Prospective cohort study of early biosignatures of response to lithium in bipolar-I-disorders: overview of the H2020-funded R-LiNK initiati…
2019
Additional file 2: Appendix S2. Proposed list of instruments used for baseline clinical assessments and longitudinal monitoring of symptoms, medication adherence and lithium response.
MOESM2 of Prospective cohort study of early biosignatures of response to lithium in bipolar-I-disorders: overview of the H2020-funded R-LiNK initiati…
2019
Additional file 2: Appendix S2. Proposed list of instruments used for baseline clinical assessments and longitudinal monitoring of symptoms, medication adherence and lithium response.
MOESM1 of Prospective cohort study of early biosignatures of response to lithium in bipolar-I-disorders: overview of the H2020-funded R-LiNK initiati…
2019
Additional file 1: Appendix S1. Country and location of centres involved in R-LiNK.
Prospective cohort study of early biosignatures of response to lithium in bipolar-I-disorders: overview of the H2020-funded R-LiNK initiative
2019
Abstract Background Lithium is recommended as a first line treatment for bipolar disorders. However, only 30% of patients show an optimal outcome and variability in lithium response and tolerability is poorly understood. It remains difficult for clinicians to reliably predict which patients will benefit without recourse to a lengthy treatment trial. Greater precision in the early identification of individuals who are likely to respond to lithium is a significant unmet clinical need. Structure The H2020-funded Response to Lithium Network (R-LiNK; http://www.r-link.eu.com/) will undertake a prospective cohort study of over 300 individuals with bipolar-I-disorder who have agreed to commence a …